{Reference Type}: Journal Article
{Title}: Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: The ProLOGUE study.
{Author}: Imafuku S;Ohata C;Okubo Y;Tobita R;Saeki H;Mabuchi T;Hashimoto Y;Murotani K;Kitabayashi H;Kanai Y;
{Journal}: J Dermatol Sci
{Volume}: 105
{Issue}: 3
{Year}: Mar 2022
{Factor}: 5.408
{DOI}: 10.1016/j.jdermsci.2022.02.007
{Abstract}: <B>BACKGROUND: </B>Real-life evidence on the quality of treatment with brodalumab in patients with plaque psoriasis based on patient-reported outcomes remains limited.<BR><B>OBJECTIVE: </B>To assess the effectiveness of brodalumab in achieving treatment satisfaction for real-life Japanese patients with psoriasis.<BR><B>METHODS: </B>As part of a single-arm, open-label, multicenter, prospective study (ProLOGUE), Psoriasis Area and Severity Index (PASI) scores, body surface area (BSA), and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) domain scores were assessed at baseline and Weeks 12 and 48 of brodalumab treatment. Patient Global Assessment (PtGA) scores were captured at Weeks 12 and 48.<BR><B>RESULTS: </B>Seventy-five patients were enrolled, of whom 73 received brodalumab. PASI scores and BSA significantly reduced from baseline at Weeks 12 and 48 (all P < 0.0001). Most (90%) patients felt the treatment was effective on the PtGA scale at Weeks 12 and 48. TSQM-9 domain scores significantly improved at Weeks 12 and 48 (all P < 0.0001). A PASI score of ≤ 2 was suggested as a treatment goal for biologic treatment of psoriasis from a receiver operating characteristic curve analysis, although some of the TSQM-9 domain scores did not improve in patients achieving this goal. No new safety signals were observed.<BR><B>CONCLUSIONS: </B>Treatment with brodalumab was associated with improved objective symptoms and satisfaction in Japanese patients with psoriasis. A PASI score of ≤ 2 as a goal for biologic treatment of psoriasis may be feasible, although achieving this PASI goal alone may be insufficient to clearly improve long-term patient satisfaction (Japan Registry of Clinical Trials identifier: jRCTs031180037).